华银健康-凯发k8娱乐官方网址

全国总部咨询电话: 400-888-1223 | 员工通道
微信二维码
返回顶部

资源下载

download

客户中心
在线留言
申请单下载

咨询热线: 400-888-1223

exome sequencing and the management of neurometabolic disorders

2016-09-05

 
abstract
background: whole-exome sequencing has transformed gene discovery and diagnosis in rare diseases. translation into disease-modifying treatments is challenging, particularly for intellectual developmental disorder. however, the exception is inborn errors of metabolism, since many of these disorders are responsive to therapy that targets pathophysiological features at the molecular or cellular level. methods: to uncover the genetic basis of potentially treatable inborn errors of metabolism, we combined deep clinical phenotyping (the comprehensive characterization of the discrete components of a patient's clinical and biochemical phenotype) with whole-exome sequencing analysis through a semiautomated bioinformatics pipeline in consecutively enrolled patients with intellectual developmental disorder and unexplained metabolic phenotypes. results: we performed whole-exome sequencing on samples obtained from 47 probands. of these patients, 6 were excluded, including 1 who withdrew from the study. the remaining 41 probands had been born to predominantly nonconsanguineous parents of european descent. in 37 probands, we identified variants in 2 genes newly implicated in disease, 9 candidate genes, 22 known genes with newly identified phenotypes, and 9 genes with expected phenotypes; in most of the genes, the variants were classified as either pathogenic or probably pathogenic. complex phenotypes of patients in five families were explained by coexisting monogenic conditions. we obtained a diagnosis in 28 of 41 probands (68%) who were evaluated. a test of a targeted intervention was performed in 18 patients (44%). conclusions: deep phenotyping and whole-exome sequencing in 41 probands with intellectual developmental disorder and unexplained metabolic abnormalities led to a diagnosis in 68%, the identification of 11 candidate genes newly implicated in neurometabolic disease, and a change in treatment beyond genetic counseling in 44%.